Impella 5.0与Impella Left Direct泵用于心脏术后心源性休克的机械循环支持:La Pitié-Salpêtrière医院经验
结果显示,平均支持时间9±7天,72.4%成功撤机,58.6%存活出院,30天和1年生存率分别为58.6%和51.7%,所有出院患者均观察到自体心脏功能恢复。作者认为Impella 5.0/LD是PCCS危重患者的良好治疗选择。
要点
- Impella 5.0/LD可为PCCS患者提供有效血流动力学支持,撤机成功率72.4%。
- 出院生存率58.6%,30天和1年生存率分别为58.6%和51.7%。
- 所有出院患者均实现自体心脏功能恢复。
核心结论
- Impella 5.0和Impella LD是PCCS危重患者的优秀治疗选择,与良好的生存结局和自体心脏恢复相关。
主要发现
- 患者平均年龄63±14岁,女性占17%,平均EuroSCORE II为22±17,射血分数为28±11%。
- 基线时69%有慢性心力衰竭,66%有扩张型心肌病,57%有瓣膜病。
- 45%的患者接受孤立瓣膜手术,38%接受孤立冠状动脉旁路移植术。
- 平均Impella支持时间为9±7天,72.4%成功撤机,58.6%存活出院。
- 出院患者中100%观察到自体心脏功能恢复;30天和1年生存率分别为58.6%和51.7%。
临床怎么用
- 对于PCCS患者,可考虑使用Impella 5.0/LD提供左心室卸载和全身灌注支持。
局限性
- 回顾性设计,样本量较小(29例),来自单中心经验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Postcardiotomy cardiogenic shock (PCCS) is associated with high mortality rates of 50-80%. Although veno-arterial extracorporeal membrane oxygenation has been used as mechanical circulatory support in patients with PCCS, it is associated with a high rate of complications and poor quality of life. The Impella 5.0 and Impella Left Direct (LD) (Impella 5.0/LD) are minimally invasive left ventricular assist devices that provide effective haemodynamic support resulting in left ventricular unloading and systemic perfusion. Our goal was to describe the outcome of patients with PCCS supported with the Impella 5.0/LD at La Pitié-Salpêtrière Hospital. METHODS: We retrospectively reviewed consecutive patients supported with the Impella 5.0/LD for PCCS between December 2010 and June 2015. Survival outcome and in-hospital complications were assessed. RESULTS: A total of 29 patients (63 ± 14 years, 17% women) with PCCS were supported with the Impella 5.0/LD. At baseline, 69% experienced chronic heart failure, 66% had dilated cardiomyopathy and 57% had valvular disease. The mean EuroSCORE II was 22 ± 17 and the ejection fraction was 28 ± 11%. Most of the patients underwent isolated valve surgery (45%) or isolated coronary artery bypass grafting (38%). The mean duration of Impella support was 9 ± 7 days. Weaning from the Impella was successful in 72.4%, and 58.6% survived to discharge. Recovery of native heart function was observed in 100% of discharged patients. Survival to 30 days and to 1 year from Impella implant was 58.6% and 51.7%, respectively. CONCLUSIONS: The Impella 5.0 and the Impella LD represent an excellent treatment option for critically ill patients with PCCS and are associated with favourable survival outcome and native heart recovery.
引用
- David CH, Quessard A, Mastroianni C, et al. Mechanical circulatory support with the Impella 5.0 and the Impella Left Direct pumps for postcardiotomy cardiogenic shock at La Pitié-Salpêtrière Hospital. Eur J Cardiothorac Surg. 2020. PMID: 31270535. doi:10.1093/ejcts/ezz179
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。